Human Disease Model Report: pancreatic carcinoma, multigenic

General Information

Name

pancreatic carcinoma, multigenic

FlyBase ID

FBhh0001548

Disease Ontology Term

pancreatic carcinoma

Parent Disease

OMIM

PANCREATIC CANCER

Overview

This report describes a multigenic model of pancreatic carcinoma (pancreatic ductal adenocarcinoma) using a combination of Drosophila genes related to a number of human genes implicated in this disease: human KRAS (using an activated form of Dmel\Ras85D), human TP53 (using RNAi-knockdown targeted to Dmel\p53), and human SMAD4 (using RNAi-knockdown targeted to Dmel\Med). Action of a fourth human gene, CDKN2A, was approximated by targeted expression of Dmel\CycE (both are involved in regulation of the mitotic cell cycle).

UAS constructs of human genes Hsap\KRAS, Hsap\TP53, and Hsap\SMAD4 have been introduced into flies, but have not been used in the context of this disease model.

'4-hit' flies were generated using various GAL4 drivers. Wing-specify drivers resulted in epithelial transformations in the wing consistent with uncontrolled growth. More general GAL4 drivers resulted in decreased survival. A genetic screen identified MEK and AURKB as potential therapeutic targets.

[updated Dec. 2023 by FlyBase; FBrf0222196]

Disease Summary Information

Disease Summary: pancreatic carcinoma, multigenic

OMIM report

[PANCREATIC CANCER](https://omim.org/entry/260350)

Human gene(s) implicated

[KRAS PROTOONCOGENE, GTPase; KRAS](https://omim.org/entry/190070)

[ACTIVIN A RECEPTOR, TYPE IB; ACVR1B](https://omim.org/entry/601300)

[TUMOR PROTEIN p53; TP53](https://omim.org/entry/191170)

[SMAD FAMILY MEMBER 4; SMAD4](https://omim.org/entry/600993)

[SERINE/THREONINE PROTEIN KINASE 11; STK11](https://omim.org/entry/602216)

Symptoms and phenotype

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent neoplastic disease of the pancreas accounting for more than 90% of all pancreatic malignancies. PDAC is the fourth most frequent cause of cancer-related deaths worldwide with a 5-year overall survival of less than 8%. (Orth et al., 2019; pubmed:31395068)

(FlyBase Curators, 2013-)

Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. [from MIM:260350; 2023.12.12]

(OMIM, 2013-)

Genetics

Somatic mutations in pancreatic cancer occur in the KRAS, CDKN2A, SMAD4, TP53, ARMET, STK11, ACVR1B, and RBBP8 genes. [from MIM:260350; 2023.12.12]

(OMIM, 2013-)

Cellular phenotype and pathology

Molecular information

External links

COSMIC gene: KRAS
COSMIC gene: TP53
COSMIC gene: SMAD4
COSMIC gene: CDKN2A
Gene2Function (human gene): KRAS
Gene2Function (human gene): TP53
Gene2Function (human gene): SMAD4
Gene2Function (human gene): CDKN2A
Gene Cards: KRAS
Gene Cards: TP53
Gene Cards: SMAD4
Gene Cards: CDKN2A
MedlinePlus (gene): TP53
MedlinePlus (gene): KRAS
MedlinePlus (gene): SMAD4
MedlinePlus (gene): CDKN2A
MARRVEL (human gene): KRAS
MARRVEL (human gene): TP53
MARRVEL (human gene): SMAD4
MARRVEL (human gene): CDKN2A
NCBI (Entrez) gene: TP53; tumor protein p53
NCBI (Entrez) gene: KRAS; KRas proto-oncogene, GTPase
NCBI (Entrez) gene: SMAD4; SMAD family member 4
NCBI (Entrez) gene: CDKN2A; cyclin dependent kinase inhibitor 2A

Disease synonyms

pancreatic cancer, somatic

pancreatic ductal adenocarcinoma

PDAC

Related Diseases

Related human health report(s)

cancer, multiple, RAS-related

cancer, multiple, TP53-related

colorectal cancer, multigenic

Ortholog Information

Human gene(s) in FlyBase

Human gene (HGNC)

Symbol / Name

SMAD4; SMAD family member 4

D. melanogaster ortholog (based on DIOPT)

Dmel\Med

(DIOPT, 2013-)

Comments on ortholog(s)

One to one: 1 human gene to 1 Drosophila gene; multiple related genes in both species.

Human gene (HGNC)

Symbol / Name

KRAS; KRas proto-oncogene, GTPase

D. melanogaster ortholog (based on DIOPT)

Dmel\Ras85D

(DIOPT, 2013-)

Comments on ortholog(s)

Many to one: 3 human genes to 1 Drosophila gene; multiple related genes in both species.

Human gene (HGNC)

Symbol / Name

TP53; tumor protein p53

D. melanogaster ortholog (based on DIOPT)

Dmel\p53

(DIOPT, 2013-)

Comments on ortholog(s)

Many to one: 3 human genes to 1 Drosophila gene.

Human gene (HGNC)

Symbol / Name

CDKN2A; cyclin dependent kinase inhibitor 2A

D. melanogaster ortholog (based on DIOPT)

Comments on ortholog(s)

No moderate- to high-scoring ortholog of CDKN2A has been identified in Drosophila.

Other mammalian ortholog(s) used

D. melanogaster Gene Information (4)

Dmel\Ras85D

Gene Snapshot

Ras oncogene at 85D (Ras85D) encodes a protein that acts downstream of several cell signals, most notably from Receptor Tyrosine Kinases, to regulate tissue growth and development. When abnormally activated it can direct developmental defects and tissue hyperplasia, mimicking aspects of human disease including Rasopathies and cancer, respectively. [Date last reviewed: 2019-03-14]

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

High-scoring ortholog of human KRAS, HRAS, and NRAS (1 Drosophila to 3 human; multiple related genes in both species).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\p53

Gene Snapshot

p53 (p53) encodes a transcriptional factor required for adaptive responses to genotoxic stress, including cell death, compensatory proliferation and DNA repair. [Date last reviewed: 2019-03-14]

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

DBDTF-U

Comments on ortholog(s)

Moderate-scoring ortholog of human TP53, TP63, TP73 (1 Drosophila to 3 human).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\CycE

Gene Snapshot

Contributions welcome

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

JAKSTAT-P

Comments on ortholog(s)

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\Med

Gene Snapshot

Medea (Med) encodes a protein that belongs to the highly conserved Smad family. It can bind its siblings encoded by Mad or Smox to facilitate signal transduction for the product of dpp or Activin ligands in the TGF-beta family. Med-complexes function as transcriptional regulators. Many developmental roles include dorsal-ventral patterning, patterning and proliferation of the wing disc and gene expression in the mushroom body of the larval brain. [Date last reviewed: 2019-03-14]

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

High-scoring ortholog of human SMAD4 (1 Drosophila to 1 human; multiple related genes in both species).

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Other Genes Used: Viral, Bacterial, Synthetic (0)

Summary of Physical Interactions (185 groups)

Ras85D

protein-protein

Interacting group

Assay

References

Ras85D - alt

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Arc1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - ave

pull down, anti tag western blot

(Maisonneuve et al., 2024)

Ras85D - CG31550

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - cindr

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - cno

two hybrid, anti tag coimmunoprecipitation, autoradiography

(Boettner and Van Aelst, 2007, Carmena et al., 2006)

Ras85D - Droj2

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - eIF3i

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - glo

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Gyc76C

anti tag coimmunoprecipitation, anti tag western blot

(Iwashita et al., 2020)

Ras85D - lark

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - mod(mdg4)

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Nf1

gtpase assay, autoradiography

(Walker et al., 2006)

Ras85D - Nop60B

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Pi3K92E

two hybrid, pull down, western blot

(Orme et al., 2006)

Ras85D - pico

two hybrid

(Lyulcheva et al., 2008)

Ras85D - Pyk

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Raf

two hybrid, anti tag coimmunoprecipitation, anti tag western blot, pull down

(Yang and Terman, 2012, Ding et al., 2010, Mishra et al., 2005)

Ras85D - rau

pull down, anti tag western blot

(Sieglitz et al., 2013)

Ras85D - Rgl

two hybrid

(Mirey et al., 2003)

Ras85D - RpL6

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpL15

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpL21

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpL23A

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpL24

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpS2

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpS27

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - spri

anti tag coimmunoprecipitation, anti tag western blot

(Jekely et al., 2005)

Ras85D - Sumo

anti tag coimmunoprecipitation, Identification by mass spectrometry, pull down, covalent binding, western blot

(Nie et al., 2009)

p53

protein-protein

Interacting group

Assay

References

p53

anti tag coimmunoprecipitation, western blot, pull down, autoradiography, coimmunoprecipitation, anti tag western blot

(Park et al., 2019, Zhang et al., 2015, Lunardi et al., 2010)

p53 - abd-A

bimolecular fluorescence complementation, fluorescence microscopy

(Bischof et al., 2018)

p53 - Acat1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Ada2b

pull down, western blot, anti tag coimmunoprecipitation, anti tag western blot

(Pankotai et al., 2013, Kusch et al., 2003)

p53 - AGO2

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Ahcy

pull down, autoradiography

(Lunardi et al., 2010)

p53 - al

anti tag coimmunoprecipitation, peptide massfingerprinting, experimental knowledge based

(Rhee et al., 2014)

p53 - ap

pull down, autoradiography

(Lunardi et al., 2010)

p53 - asf1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - asp

pull down, autoradiography

(Lunardi et al., 2010)

p53 - aub

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Bap60

pull down, autoradiography

(Lunardi et al., 2010)

p53 - boly

pull down, autoradiography

(Lunardi et al., 2010)

p53 - bowl

two hybrid array

(Shokri et al., 2019)

p53 - Brd8

pull down, autoradiography

(Lunardi et al., 2010)

p53 - bsf

pull down, autoradiography

(Lunardi et al., 2010)

p53 - bsk

anti tag coimmunoprecipitation, western blot

(Gowda et al., 2012)

p53 - Cep89

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG1074

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG1137

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG1602

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG1647

two hybrid array

(Shokri et al., 2019)

p53 - CG1958

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG3610

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG4854

anti tag coimmunoprecipitation, peptide massfingerprinting, experimental knowledge based, two hybrid array

(Shokri et al., 2019, Rhee et al., 2014)

p53 - CG6325

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG6333

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG6686

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG7139

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG7379

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG7387

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG7634

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG8236

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG8851

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG10333

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG11035

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG12861

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG13436

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG15269

two hybrid array

(Shokri et al., 2019)

p53 - CG30059

pull down, autoradiography

(Lunardi et al., 2010)

p53 - CG32985

pull down, autoradiography

(Lunardi et al., 2010)

p53 - chb

pull down, autoradiography

(Lunardi et al., 2010)

p53 - chinmo

two hybrid array

(Shokri et al., 2019)

p53 - Coprox

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Corp

pull down, western blot, autoradiography, anti tag coimmunoprecipitation, anti tag western blot

(Chakraborty et al., 2015)

p53 - cort

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Cp110

pull down, autoradiography

(Lunardi et al., 2010)

p53 - croc

two hybrid array

(Shokri et al., 2019)

p53 - CycG

two hybrid, anti tag coimmunoprecipitation, western blot

(Bayer et al., 2017)

p53 - Cyp6a22

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Cyp6d5

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Cyt-c1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Daxx

two hybrid, pull down, autoradiography

(Lunardi et al., 2010, Bodai et al., 2007)

p53 - Dlip3

anti tag coimmunoprecipitation, peptide massfingerprinting, experimental knowledge based

(Rhee et al., 2014)

p53 - Dll

two hybrid array

(Shokri et al., 2019)

p53 - Dph1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - dsx

pull down, autoradiography

(Lunardi et al., 2010)

p53 - dup

pull down, autoradiography

(Lunardi et al., 2010)

p53 - dyl

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Fdh

pull down, autoradiography

(Lunardi et al., 2010)

p53 - fdl

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Gas8

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Gcn5

pull down, western blot, anti bait coimmunoprecipitation

(Kusch et al., 2003)

p53 - grau

pull down, autoradiography

(Lunardi et al., 2010)

p53 - gry

pull down, autoradiography

(Lunardi et al., 2010)

p53 - gus

pull down, autoradiography

(Lunardi et al., 2010)

p53 - hay

anti bait coimmunoprecipitation, western blot

(Villicaña et al., 2013)

p53 - hmw

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Hsf

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Hsp23

anti tag coimmunoprecipitation, peptide massfingerprinting, experimental knowledge based

(Rhee et al., 2014)

p53 - Hsp26

anti tag coimmunoprecipitation, peptide massfingerprinting, experimental knowledge based, anti bait coimmunoprecipitation, western blot

(Lei et al., 2017, Rhee et al., 2014)

p53 - Hsp27

anti bait coimmunoprecipitation, western blot

(Lei et al., 2017)

p53 - Ice2

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Idi

pull down, autoradiography

(Lunardi et al., 2010)

p53 - if

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Imp

pull down, autoradiography

(Lunardi et al., 2010)

p53 - INPP5E

pull down, autoradiography

(Lunardi et al., 2010)

p53 - jp

pull down, autoradiography

(Lunardi et al., 2010)

p53 - ktub

two hybrid array

(Shokri et al., 2019)

p53 - lost

pull down, autoradiography

(Lunardi et al., 2010)

p53 - lwr

two hybrid, pull down, autoradiography

(Hu et al., 2017.6.13, Pardi et al., 2011)

p53 - Mmp2

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Mppa

pull down, autoradiography

(Lunardi et al., 2010)

p53 - mrj

pull down, autoradiography

(Lunardi et al., 2010)

p53 - mrn

anti tag coimmunoprecipitation, anti tag western blot, western blot, anti bait coimmunoprecipitation, pull down, autoradiography

(Villicaña et al., 2013)

p53 - mRpL16

pull down, autoradiography

(Lunardi et al., 2010)

p53 - mtgo

pull down, autoradiography

(Lunardi et al., 2010)

p53 - mTTF

pull down, autoradiography

(Lunardi et al., 2010)

p53 - mu2

pull down, autoradiography

(Lunardi et al., 2010)

p53 - mura

pull down, autoradiography

(Lunardi et al., 2010)

p53 - ND-51L2

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Nna1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Non1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - nord

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Nprl3

pull down, autoradiography

(Lunardi et al., 2010)

p53 - pho

bimolecular fluorescence complementation, fluorescence microscopy, two hybrid array

(Shokri et al., 2019)

p53 - PPO2

pull down, autoradiography

(Lunardi et al., 2010)

p53 - raskol

pull down, autoradiography

(Lunardi et al., 2010)

p53 - RPA1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - RtcB

pull down, autoradiography

(Lunardi et al., 2010)

p53 - SA1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Sas-6

pull down, autoradiography

(Lunardi et al., 2010)

p53 - sima

pull down, autoradiography

(Lunardi et al., 2010)

p53 - sip3

enzymatic study, western blot

(Yamasaki et al., 2007)

p53 - Sirt1

anti tag coimmunoprecipitation, western blot

(Bauer et al., 2009)

p53 - Sox102F

two hybrid array

(Shokri et al., 2019)

p53 - spoon

pull down, autoradiography

(Lunardi et al., 2010)

p53 - sqh

pull down, autoradiography

(Lunardi et al., 2010)

p53 - ssx

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Su(var)2-10

two hybrid, pull down, autoradiography

(Pardi et al., 2011)

p53 - Svil

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Taf3

two hybrid, pull down, autoradiography

(Bereczki et al., 2008)

p53 - Taf11

anti tag coimmunoprecipitation, peptide massfingerprinting, experimental knowledge based

(Rhee et al., 2014)

p53 - tbrd-1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Tfb1

anti bait coimmunoprecipitation, western blot

(Villicaña et al., 2013)

p53 - Timmdc1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Tm1

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Tom40

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Topors

pull down, autoradiography

(Secombe and Parkhurst, 2004)

p53 - toy

two hybrid array, pull down, autoradiography

(Shokri et al., 2019, Lunardi et al., 2010)

p53 - TTLL5

pull down, autoradiography

(Lunardi et al., 2010)

p53 - TwdlW

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Uba2

two hybrid, pull down, autoradiography

(Pardi et al., 2011)

p53 - Ubc6

anti tag coimmunoprecipitation, western blot, pull down, anti tag western blot, coimmunoprecipitation

(Chen et al., 2011)

p53 - Ubx

bimolecular fluorescence complementation, fluorescence microscopy

(Bischof et al., 2018)

p53 - uno

pull down, autoradiography

(Lunardi et al., 2010)

p53 - Usp7

enzymatic study, western blot

(van der Knaap et al., 2005)

p53 - Utx

anti bait coimmunoprecipitation, western blot

(Zhang et al., 2013)

p53 - Vha36-2

pull down, autoradiography

(Lunardi et al., 2010)

p53 - yki

anti tag coimmunoprecipitation, anti tag western blot

(Di Cara et al., 2015)

RNA-RNA

Interacting group

Assay

References

p53 - mir-219

luminiscence technology, fluorescence technology

(Barrio et al., 2014)

p53 - mir-279

luminiscence technology

(Barrio et al., 2014)

p53 - mir-283

luminiscence technology, fluorescence technology

(Barrio et al., 2014)

p53 - mir-305

luminiscence technology, fluorescence technology, necessary binding region

(Barrio et al., 2014)

p53 - mir-1014

luminiscence technology

(Barrio et al., 2014)

CycE

protein-protein

Interacting group

Assay

References

CycE - ago

anti tag coimmunoprecipitation, anti tag western blot, pull down, western blot

(Szuplewski et al., 2009, Moberg et al., 2001)

CycE - caup

anti tag coimmunoprecipitation, anti tag western blot

(Barrios et al., 2015)

CycE - Cdk1

two hybrid

(Finley et al., 1996)

CycE - Cdk2

anti bait coimmunoprecipitation, western blot, experimental knowledge based, anti tag coimmunoprecipitation, anti tag western blot

(Guruharsha et al., 2011, Wang and Kalderon, 2009, Lane et al., 1996, Knoblich et al., 1994)

CycE - Cul4

anti bait coimmunoprecipitation, anti tag western blot

(Higa et al., 2006)

CycE - dap

anti bait coimmunoprecipitation, western blot

(Lane et al., 1996)

CycE - mi

pull down, western blot

(Szuplewski et al., 2009)

CycE - osa

anti bait coimmunoprecipitation, western blot

(Baig et al., 2010)

CycE - pros

anti tag coimmunoprecipitation, western blot

(Berger et al., 2010)

CycE - Snr1

anti bait coimmunoprecipitation, western blot, pull down

(Zraly et al., 2004)

CycE - Z600

two hybrid, surface plasmon resonance, anti bait coimmunoprecipitation, peptide massfingerprinting, pull down, autoradiography

(Gawlinski et al., 2007)

Med

protein-protein

Interacting group

Assay

References

Med - eIF4A

anti tag coimmunoprecipitation, anti tag western blot

(Li and Li, 2006)

Med - fuss

two hybrid, anti tag coimmunoprecipitation, anti tag western blot

(Fischer et al., 2012)

Med - hiw

pull down, autoradiography, two hybrid

(McCabe et al., 2004)

Med - lwr

two hybrid

(Miles et al., 2008)

Med - Mad

anti tag coimmunoprecipitation, autoradiography, pull down, tag visualisation, anti tag western blot

(Cheng et al., 2013, Kazemian et al., 2013, Kamiya et al., 2008, Takaesu et al., 2006, Inoue et al., 1998, Wisotzkey et al., 1998)

Med - Ote

fluorescent resonance energy transfer, fluorescence microscopy, anti tag coimmunoprecipitation, western blot, anti bait coimmunoprecipitation, anti tag western blot

(Jiang et al., 2008)

Med - Rel

two hybrid array

(Shokri et al., 2019)

Med - Smox

anti tag coimmunoprecipitation, anti tag western blot

(Takaesu et al., 2006)

Med - Snoo

anti tag coimmunoprecipitation, anti tag western blot

(Quijano et al., 2010, Takaesu et al., 2006)

RNA-RNA

Interacting group

Assay

References

Med - mir-124

luminiscence technology

(Sun et al., 2012)

Alleles Reported to Model Human Disease (Disease Ontology) (72 alleles)

Hsap\KRAS

Models Based on Experimental Evidence ( 2 )

Allele

Disease

Evidence

References

Hsap\KRAS^G12D.UAS

model of Noonan syndrome

CEA

(Das et al., 2021)

model of Noonan syndrome with multiple lentigines

CEA

(Das et al., 2021)

model of cancer

CEA

(Das et al., 2021)

Hsap\KRAS^G12V.UAS

model of acute myeloid leukemia

CEA

(Zhu et al., 2022)

model of cancer

CEA

(Zhu et al., 2022)

Modifiers Based on Experimental Evidence ( 1 )

Allele

Disease

Interaction

References

Hsap\KRAS^G12V.UAS

model of acute myeloid leukemia

is ameliorated by sima^HMS00833

(Zhu et al., 2022)

is ameliorated by sima^JF02105

(Zhu et al., 2022)

is ameliorated by tgo^GL01042

(Zhu et al., 2022)

is ameliorated by tgo^JF02302

(Zhu et al., 2022)

Hsap\TP53

Models Based on Experimental Evidence ( 5 )

Allele

Disease

Evidence

References

Hsap\TP53^R175H

model of cancer

CEA with p53^-ns, p53^TM3

(D'Brot et al., 2017)

Hsap\TP53^G245S

model of cancer

CEA with p53^-ns, p53^TM3

(D'Brot et al., 2017)

Hsap\TP53^R248Q

model of cancer

CEA with p53^-ns, p53^TM3

(D'Brot et al., 2017)

Hsap\TP53^R273C

model of cancer

CEA with p53^-ns, p53^TM3

(D'Brot et al., 2017)

Hsap\TP53^R273H

model of cancer

CEA with p53^-ns, p53^TM3

(D'Brot et al., 2017)

Modifiers Based on Experimental Evidence ( 0 )

Allele

Disease

Interaction

References

Ras85D

Models Based on Experimental Evidence ( 17 )

Allele

Disease

Evidence

References

Ras85D^HMS01294

model of Noonan syndrome 3

CEA

(Cattaneo et al., 2020)

Ras85D^G12V.UAS

model of cancer

CEA with RhoGEF2^RE.UAS

(Khoo et al., 2013)

CEA with Rok^CAT.UAS

(Khoo et al., 2013)

CEA with sqh^{E20E21.UAS.cCa}

(Khoo et al., 2013)

Ras85D^G13Q.UAS

model of cancer

CEA

(Xu et al., 2023)

CEA with Pten^HMS00044, Rbf^HMS03004

(Parkhitko et al., 2021)

Ras85D^N17.UAS

model of Noonan syndrome 3

CEA

(Cattaneo et al., 2020)

Ras85D^Q13.UAS

model of cancer

CEA

(Tamamouna et al., 2021)

Ras85D^V12.GMR

model of cancer

CEA

(Okada et al., 2023)

Ras85D^V12.S35.UAS

model of cardiomyopathy

CEA

(Yu et al., 2013)

model of carcinoma

CEC

(Karim and Rubin, 1998)

Ras85D^V12.UAS

model of carcinoma

CEA

(Martínez-Abarca Millán and Martín-Bermudo, 2023, Ito and Igaki, 2021, Kong et al., 2021, Rackley et al., 2021, Soler Beatty et al., 2021, Wei et al., 2021, Wu et al., 2021, Murcia et al., 2019, Zoranovic et al., 2018, Pérez et al., 2015, Igaki et al., 2006)

CEA with dlg1^GD4689

(Santabárbara-Ruiz and Léopold, 2021)

CEA with scrib⁶⁷³

(Amcheslavsky et al., 2018, Pérez et al., 2015)

CEC

(Rosen et al., 2019, Karim and Rubin, 1998)

CEC with scrib¹

(Rosen et al., 2019)

CEA with l(2)gl⁴

(Ding et al., 2022, Singh et al., 2022, Ito and Igaki, 2021, Wu et al., 2021, Mishra-Gorur et al., 2019, Zhang et al., 2019, Srivastava et al., 2007, Igaki et al., 2006)

CEA with Lkb1^4A4-2

(Rackley et al., 2021)

CEA with scrib¹

(Kong et al., 2021, Mishra-Gorur et al., 2019, Srivastava et al., 2007, Igaki et al., 2006, Uhlirova and Bohmann, 2006)

CEA with dlg1¹⁴

(Ito and Igaki, 2021, Igaki et al., 2006)

CEA with shg^k03401

(Igaki et al., 2006)

CEA with msn³²⁰⁸

(Kong et al., 2021)

CEA with sna^UAS.cAa

(Wu et al., 2021)

CEA with scrib^KK101128

(Murcia et al., 2019)

CEA with scrib^HMJ21977

(Snigdha et al., 2021)

CEA with Csk^Q156Stop

(Hirabayashi and Cagan, 2015)

CEA with Csk^Q156Stop, InR^A1325D.UAS

(Hirabayashi and Cagan, 2015)

model of cancer

CEA with fmt¹

(Ma et al., 2017)

CEA with PpV^Δ1

(Ma et al., 2017)

CEA with l(2)gl⁴

(Guo et al., 2020, Ma et al., 2017, Ma et al., 2013, Pagliarini and Xu, 2003)

CEA with PpV^GD7532

(Ma et al., 2017)

CEA

(Khalili et al., 2023, Martínez-Abarca Millán et al., 2023, Enomoto et al., 2021, Santabárbara-Ruiz and Léopold, 2021, Tamamouna et al., 2021, Ma et al., 2020, Jung et al., 2019, Rives-Quinto et al., 2017, Chabu and Xu, 2014, Hirabayashi et al., 2013, Ma et al., 2013)

CEA with scrib⁶⁷³

(Katheder et al., 2017, Pérez et al., 2017)

CEA with scrib¹

(Kakemura and Igaki, 2024, Cong et al., 2021, Hodgson et al., 2021, Katheder et al., 2017, Figueroa-Clarevega and Bilder, 2015, Külshammer et al., 2015, Stickel and Su, 2014, Willoughby et al., 2013, Wu et al., 2010, Pagliarini and Xu, 2003)

CEA with dlg1^GD4689

(Katheder et al., 2017, Muzzopappa et al., 2017, Figueroa-Clarevega and Bilder, 2015, Willecke et al., 2011)

CEA with scrib^j7B3

(Waghmare et al., 2024, Pagliarini and Xu, 2003)

CEA with Src64B^UAS.cCa

(Enomoto et al., 2021)

CEA with dlg1¹⁴

(Kakemura and Igaki, 2024, Pagliarini and Xu, 2003)

CEA with baz⁴

(Pagliarini and Xu, 2003)

CEA with sdt^XN

(Pagliarini and Xu, 2003)

CEA with Cdc42¹

(Pagliarini and Xu, 2003)

CEA with dor^C107

(Chi et al., 2010)

CEA with dor⁸

(Chi et al., 2010)

CEA with dor^D185

(Chi et al., 2010)

CEA with car^RNAi.UAS

(Chi et al., 2010)

CEA with Vps16A^RNAi.UAS.WIZ

(Chi et al., 2010)

CEA with upd1^UAS.cUa

(Wu et al., 2010)

CEA with upd2^UAS.cUa

(Wu et al., 2010)

CEA with upd1^UAS.cUa, upd2^UAS.cUa, upd3^UAS.cUa

(Wu et al., 2010)

CEA with l(2)gl^unspecified

(Xu et al., 2023, Wu et al., 2010)

CEA with pnut^GD1512

(Gerlach et al., 2018)

CEC with l(2)gl⁴

(Ma et al., 2014)

CEA with Hsap\S100A4^wt.UAS

(Ismail et al., 2017)

CEA with scrib^RNAi.UAS.cUa

(Hodgson et al., 2021)

CEA with Csk^Q156Stop

(Hirabayashi et al., 2013)

CEA with scrib^KK101128

(Muzzopappa et al., 2017)

CEA with mud^JF02911

(Muzzopappa et al., 2017)

CEA with mud^HMS01458

(Muzzopappa et al., 2017)

CEA with N^RNAi.P.UAS

(Tamamouna et al., 2021)

CEA with N^DN.UAS.cUa

(Xu et al., 2023)

CEA with emei^GD3587

(Ma et al., 2020)

CEA with Rox8^GD11645

(Guo et al., 2020)

CEA with BacA\p35^UAS.cHa

(Khalili et al., 2023)

CEA with dlg1^RNAi.UAS.cUa

(Bakopoulos et al., 2023)

model of intestinal cancer

CEA

(Cabrera et al., 2023, Nászai et al., 2021)

CEA with Apc2^N175K, Apc^Q8

(Martorell et al., 2014, Martorell et al., 2014)

model of colorectal cancer

CEA

(Bangi et al., 2012)

model of leukemia

CEA

(Arefin et al., 2017)

CEA with l(2)gl^KK100777

(Arefin et al., 2017)

CEA with scrib^KK101128

(Arefin et al., 2017)

model of benign neoplasm

CEA with Alg9^c02021

(de Vreede et al., 2018)

DOES NOT model cancer

CEA with Hsap\S100A4^Δ2.UAS

(Ismail et al., 2017)

model of heart disease

CEA

(Karekar et al., 2021)

model of prostate cancer

CEA

(Rambur et al., 2020)

model of high grade glioma

CEA

(Kumar et al., 2024)

CEA with Pten^RNAi.UAS.cUa

(Cheng et al., 2016)

model of kidney cancer

CEA

(Zeng et al., 2010)

model of ovarian carcinoma

CEA with aPKC^ΔN.UAS

(Hsi et al., 2023)

model of hypertrophic cardiomyopathy

CEA

(Petersen et al., 2022)

Ras85D^V12.ey

model of carcinoma

CEC

(Karim and Rubin, 1998)

Ras85D^V12.cUa.UAS

model of cervical cancer

CEA

(Padash Barmchi et al., 2016)

CEA with Hsap\UBE3A^UAS.cRa, HPV18\E6^UAS.Tag:MYC

(Padash Barmchi et al., 2016)

CEA with Hsap\UBE3A^UAS.cRa, HPV18\E6^{V158A.UAS.Tag:MYC}

(Padash Barmchi et al., 2016)

model of cancer

CEA with l(2)gl⁴

(Fangninou et al., 2023, Liu et al., 2022, Yang et al., 2022)

CEA with Ptp61F^Δ

(Liu et al., 2022)

CEA with Syx7³¹¹⁹

(Liu et al., 2022)

CEA with Rabex-5³⁶⁷²

(Liu et al., 2022)

CEA with Vps36²⁵⁸⁶

(Liu et al., 2022)

CEA with TSG101^P26

(Liu et al., 2022)

CEA with N^DN.UAS.cUa

(Lee et al., 2021)

CEA with dlg1^RNAi.UAS.cUa

(Lodge et al., 2021)

CEA

(Yang et al., 2022, Dong et al., 2021, Yeom et al., 2021, Dunn et al., 2018, Vicente et al., 2018)

CEA with scrib¹

(Yang et al., 2022, Khezri et al., 2021)

CEA with baz⁴

(Yang et al., 2022)

CEA with fmt¹

(Yang et al., 2022)

CEA with dlg1^GD4689

(Yang et al., 2022)

CEA with Ptip³⁸⁰⁴

(Dong et al., 2021)

model of colorectal cancer

CEA

(Zipper et al., 2022)

CEA with Pten^sgRNA.UAS

(Zipper et al., 2022)

CEA with Med^sgRNA.UAS

(Zipper et al., 2022)

CEA with cic^sgRNA.UAS

(Zipper et al., 2022)

CEA with Apc2^sgRNA.UAS

(Zipper et al., 2022)

CEA with Apc^sgRNA.UAS

(Zipper et al., 2022)

CEA with p53^sgRNA.UAS

(Zipper et al., 2022)

CEA with p53^RNAi.UAS.cUa, Pten^GD13500, Apc^RNAi.UAS.cUa, Med^RNAi.UAS.cUa

(Bangi et al., 2016)

CEA with p53^RNAi.UAS.cUa, Pten^GD13500, Apc^RNAi.UAS.cUa

(Bangi et al., 2016)

CEA with p53^RNAi.UAS.cUa, Apc^RNAi.UAS.cUa, Med^RNAi.UAS.cUa

(Bangi et al., 2016)

CEA with Pten^GD13500, Apc^RNAi.UAS.cUa, Med^RNAi.UAS.cUa

(Bangi et al., 2016)

model of cardiomyopathy

CEA

(Yu et al., 2013)

model of adenocarcinoma

CEA with l(2)gl^GD4047

(Casas-Tintó et al., 2016)

CEA with l(2)gl^GD4047, wupA^JF02172

(Casas-Tintó et al., 2016)

model of carcinoma

CEA

(Guo et al., 2024, Hogan et al., 2009)

CEA with l(2)gl⁴

(Sun et al., 2019)

CEA with dlg1^HMS00172

(Toggweiler et al., 2016)

model of intestinal cancer

CEA with Apc^Q8

(Campbell et al., 2019)

CEA

(Kim et al., 2022, Dai et al., 2020, Singh et al., 2016)

CEA with Apc2^N175K, Apc^Q8

(Parisi et al., 2023)

CEA with Apc^GD1333, p53^GD4483

(Quintero and Bangi, 2023)

CEA with Apc^GD1333, Pten^RNAi.UAS.cUa, p53^GD4483

(Quintero and Bangi, 2023)

CEA with Apc^GD1333, Med^GD1483, p53^GD4483

(Quintero and Bangi, 2023)

model of high grade glioma

CEA with Pten^{RNAi.Exel.UAS}

(Gangwani et al., 2020)

CEA

(Liu et al., 2021)

model of brain cancer

CEA with dlg1^GD4689

(Manzanero-Ortiz et al., 2021)

CEA with l(2)gl^KK100777

(Manzanero-Ortiz et al., 2021)

CEA with wts^KK101055

(Manzanero-Ortiz et al., 2021)

CEA with scrib⁶⁷³

(Manzanero-Ortiz et al., 2021)

Ras85D^V152G.UASp

model of Noonan syndrome 3

CEA

(Cattaneo et al., 2020)

Ras85D^{G12V.UAS.Tag:FLAG,Tag:polyHis}

model of cancer

CEA

(Washington et al., 2020)

Ras85D^{Y4F.G12V.UAS.Tag:FLAG,Tag:polyHis}

model of cancer

CEA

(Washington et al., 2020)

Ras85D^V12.QUAS.cHa

model of cancer

CEA with scrib¹

(Hodgson et al., 2021)

Ras85D^V12.QUAS.cLa

model of cancer

CEA with scrib^{QUAS.HMS01490}

(Bakopoulos et al., 2023, Lodge et al., 2021)

Ras85D^G12D.UAS.cSa

model of pancreatic ductal adenocarcinoma

CEA with CycE^{UAS.Tag:HA.Medsh}, Med^{RNAi.UAS.CycE-HA}, p53^{RNAi.UAS.RasG12D}

(Sekiya et al., 2023)

Ras85D^{G12D.UAS.p53sh}

model of pancreatic ductal adenocarcinoma

CEA with CycE^{UAS.Tag:HA.Medsh}, Med^{RNAi.UAS.CycE-HA}, p53^{RNAi.UAS.RasG12D}

(Sekiya et al., 2023)

Modifiers Based on Experimental Evidence ( 19 )

Allele

Disease

Interaction

References

Ras85D^HMS01294

ameliorates hematologic cancer

modeled by mxc¹

(Kurihara et al., 2020)

Ras85D^ΔC40B

ameliorates multiple endocrine neoplasia type 2B

modeled by Ret^MEN2B.GMR

(Read et al., 2005)

Ras85D⁰⁶⁶⁷⁷

ameliorates autosomal dominant cerebellar ataxia

modeled by Hsap\ATXN1^82Q.UAS

(Park et al., 2013)

ameliorates multiple endocrine neoplasia type 2B

modeled by Ret^MEN2B.GMR

(Read et al., 2005)

ameliorates multiple endocrine neoplasia type 2A

modeled by Ret^MEN2A.GMR

(Read et al., 2005)

ameliorates alveolar rhabdomyosarcoma

modeled by Hsap\FOXO1::Hsap\PAX7^UAS.cGa

(Galindo et al., 2006)

Ras85D^G13Q.UAS

model of cancer

is exacerbated by ITP^UAS.F

(Xu et al., 2023)

Ras85D^N17.UAS

ameliorates brain glioma

modeled by btl::Egfr^λ.UAS, Pi3K92E^{UAS.Tag:MYC,Tag:PM(hKRAS)}

(Read et al., 2009)

Ras85D^Q13.UAS

model of cancer

is ameliorated by Cat^UAS.cAa

(Tamamouna et al., 2021)

is ameliorated by Sod1^UAS.cAa

(Tamamouna et al., 2021)

is ameliorated by btl^DN.UAS

(Tamamouna et al., 2021)

Ras85D^V12.GMR

model of cancer

is ameliorated by InR^GL00139

(Okada et al., 2023)

is ameliorated by InR^JF01183

(Okada et al., 2023)

is ameliorated by InR^JF01482

(Okada et al., 2023)

is ameliorated by InR^K1409A.UAS

(Okada et al., 2023)

is ameliorated by NetB^Δ

(Okada et al., 2023)

is ameliorated by NetB^KK103672

(Okada et al., 2023)

is ameliorated by NetB^VSH330183

(Okada et al., 2023)

is ameliorated by unc-5^HMS01099

(Okada et al., 2023)

is ameliorated by unc-5^KK102074

(Okada et al., 2023)

is ameliorated by unc-5^MI04273

(Okada et al., 2023)

Ras85D^V12.UAS

model of carcinoma

is exacerbated by mys^RNAi.UAS.cUa

(Martínez-Abarca Millán and Martín-Bermudo, 2023)

is exacerbated by mys^RNAi.UAS.cUa

(Martínez-Abarca Millán and Martín-Bermudo, 2023)

is ameliorated by Atg1^GD7149

(Pérez et al., 2015)

is ameliorated by HAdV-C\E4orf4^UAS.cPa

(Rosen et al., 2019)

is ameliorated by HAdV-C\E4orf4^UAS.cPb

(Rosen et al., 2019)

is exacerbated by dap^HMS01610

(Ito and Igaki, 2021)

is exacerbated by dap^HMS05362

(Ito and Igaki, 2021)

is ameliorated by pnt^P1.UAS

(Ito and Igaki, 2021)

is exacerbated by hep^Act.UAS

(Uhlirova and Bohmann, 2006)

is exacerbated by egr^UAS.cIa

(Igaki et al., 2006)

is exacerbated by ZnT86D^KK101698

(Wei et al., 2021)

is exacerbated by msn¹⁷²

(Kong et al., 2021)

is exacerbated by msn³²⁰⁸

(Kong et al., 2021)

is exacerbated by l(2)gl⁴

(Wu et al., 2021)

is exacerbated by sna^UAS.cAa

(Wu et al., 2021)

is ameliorated by rl^GD4697

(Murcia et al., 2019)

is exacerbated by Tsp29Fb^GD1018

(Zoranovic et al., 2018)

is ameliorated by Tsp29Fb^UAS.Tag:HA

(Zoranovic et al., 2018)

is ameliorated by Raf^DN.UAS

(Zoranovic et al., 2018)

is ameliorated by Hsap\CDKN1A^UAS.cHa

(Karim and Rubin, 1998)

is ameliorated by Raf^XS-2541

(Karim and Rubin, 1998)

is exacerbated by rl^Sem

(Karim and Rubin, 1998)

is exacerbated by Egfrap^ΔSH2

(Soler Beatty et al., 2021)

is exacerbated by Egfrap^HMJ23378

(Soler Beatty et al., 2021)

is exacerbated by Egfrap^LS

(Soler Beatty et al., 2021)

is exacerbated by Egfrap^L

(Soler Beatty et al., 2021)

is exacerbated by PVRAP^HMJ23233

(Soler Beatty et al., 2021)

model of cancer

is ameliorated by Sec15^KK101708

(Chabu and Xu, 2014)

is ameliorated by Sec6^GD11616

(Chabu and Xu, 2014)

is ameliorated by Sec8^KK101531

(Chabu and Xu, 2014)

is ameliorated by Sec15¹

(Chabu and Xu, 2014)

is ameliorated by Sec15^GD12109

(Chabu and Xu, 2014)

is ameliorated by Src64B^GD12263

(Ma et al., 2013)

is ameliorated by Dronc^NIG.8091R

(Waghmare et al., 2024)

is ameliorated by bsk^DN.UAS

(Waghmare et al., 2024)

is ameliorated by sgg^S9A.UAS

(Waghmare et al., 2024)

is ameliorated by yki^RNAi.C.UAS

(Waghmare et al., 2024)

is ameliorated by yki^RNAi.N.UAS

(Waghmare et al., 2024)

is ameliorated by chinmo¹

(Enomoto et al., 2021)

is exacerbated by PVRAP¹

(Martínez-Abarca Millán et al., 2023)

is exacerbated by PVRAP^HMJ23233

(Martínez-Abarca Millán et al., 2023)

is exacerbated by by^33c

(Martínez-Abarca Millán et al., 2023)

is exacerbated by by^VSH330366

(Martínez-Abarca Millán et al., 2023)

is exacerbated by Csk^Q156Stop

(Hirabayashi et al., 2013)

is exacerbated by emei¹

(Ma et al., 2020)

is exacerbated by emei²

(Ma et al., 2020)

is exacerbated by emei³

(Ma et al., 2020)

is ameliorated by Arc1^esm18

(Khalili et al., 2023)

is exacerbated by Nek2^UAS.GFP

(Das et al., 2013)

model of intestinal cancer

is ameliorated by shg^HMS00693

(Cabrera et al., 2023)

is ameliorated by shg^JF02769

(Cabrera et al., 2023)

is ameliorated by Cortactin^HMS00658

(Cabrera et al., 2023)

is ameliorated by Cortactin^KK108594

(Cabrera et al., 2023)

exacerbates alveolar rhabdomyosarcoma

modeled by Hsap\FOXO1::Hsap\PAX7^UAS.cGa

(Galindo et al., 2006)

exacerbates gastrointestinal system cancer

modeled by Apc2^g10, Apc^Q8

(Wang et al., 2013)

model of colorectal cancer

is ameliorated by Jra^NIG.2275R

(Bangi et al., 2012)

is ameliorated by bsk^DN.UAS

(Bangi et al., 2012)

is ameliorated by bsk^HMS00777

(Bangi et al., 2012)

is exacerbated by hep^Act.UAS

(Bangi et al., 2012)

is exacerbated by imd^UAS.cGa

(Bangi et al., 2012)

is ameliorated by Timp^UAS.cPa

(Bangi et al., 2012)

ameliorates cancer

modeled by dlg1^A40.2

(Parisi et al., 2014)

exacerbates carcinoma

modeled by scrib¹

(Brumby and Richardson, 2003)

modeled by arm^UAS.Exel

(Zhang et al., 2019)

model of prostate cancer

is ameliorated by Egfr^GD1654

(Rambur et al., 2020)

is ameliorated by Pi3K92E^HMC05152

(Rambur et al., 2020)

is ameliorated by mTor^GL00156

(Rambur et al., 2020)

is ameliorated by rl^HMS00173

(Rambur et al., 2020)

is ameliorated by spi^HMS01120

(Rambur et al., 2020)

exacerbates intestinal cancer

modeled by Rab11^KK108297

(Nie et al., 2019)

exacerbates cancer

modeled by Hipk^UAS.Tag:HA

(Blaquiere et al., 2018)

model of kidney cancer

is ameliorated by Pka-C1^B3

(Zeng et al., 2010)

is ameliorated by mTor^ΔP

(Zeng et al., 2010)

exacerbates Alzheimer's disease 1

modeled by Hsap\APP^{Aβ42.UAS.cUa}

(Cheng et al., 2021)

exacerbates hematologic cancer

modeled by mxc¹

(Kurihara et al., 2020)

Ras85D^V12.ey

model of carcinoma

is ameliorated by Raf^XS-2541

(Karim and Rubin, 1998)

Ras85D^e1B

ameliorates alveolar rhabdomyosarcoma

modeled by Hsap\FOXO1::Hsap\PAX7^UAS.cGa

(Galindo et al., 2006)

exacerbates viral infectious disease

modeled by EBV\BZLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

exacerbates infectious mononucleosis

modeled by EBV\BZLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

exacerbates Epstein-Barr virus hepatitis

modeled by EBV\BZLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

ameliorates gastrointestinal system cancer

modeled by Apc2^g10, Apc^Q8

(Wang et al., 2013)

exacerbates tuberous sclerosis

modeled by Tsc1^UAS.cTa, gig^UAS.cTa

(Tapon et al., 2001)

ameliorates cancer

modeled by Alk^UAS.cLa

(Wolfstetter et al., 2020)

Ras85D^e2F

ameliorates alveolar rhabdomyosarcoma

modeled by Hsap\FOXO1::Hsap\PAX7^UAS.cGa

(Galindo et al., 2006)

Ras85D^unspecified

ameliorates neurofibromatosis

modeled by Nf1^E2

(Walker et al., 2006)

Ras85D^V12.cUa.UAS

model of cancer

is exacerbated by Ptp61F^Δ

(Liu et al., 2022)

is exacerbated by ex^e1

(Liu et al., 2022)

is exacerbated by Not3^KK102144

(Vicente et al., 2018)

is exacerbated by M6^W186stop

(Dunn et al., 2018)

is ameliorated by Ptip³⁸⁰⁴

(Dong et al., 2021)

is exacerbated by p53^UAS.cUa

(Dong et al., 2021)

is ameliorated by Ilp8^MI00727

(Yeom et al., 2021)

model of intestinal cancer

is ameliorated by Cortactin^HMS00658

(Kim et al., 2022)

is exacerbated by Clbn^1Q

(Dai et al., 2020)

model of high grade glioma

is ameliorated by Nmnat^RNAi.UAS.cUa

(Liu et al., 2021)

is ameliorated by Dcp-1^RNAi.UAS.cUa

(Liu et al., 2021)

is exacerbated by Nmnat^UAS.PC

(Liu et al., 2021)

exacerbates carcinoma

modeled by Nkap^GD11807

(Guo et al., 2024)

model of carcinoma

is exacerbated by Nkap^GD11807

(Guo et al., 2024)

Ras85D^GD12553

ameliorates colorectal cancer

modeled by Src42A^CA.UAS

(Cordero et al., 2014)

modeled by Src64B^UAS.cCa

(Cordero et al., 2014)

ameliorates neurofibromatosis

modeled by Nf1^JF01866

(Georganta et al., 2021)

Ras85D^KK108029

ameliorates colorectal cancer

modeled by Src42A^CA.UAS

(Cordero et al., 2014)

modeled by Src64B^UAS.cCa

(Cordero et al., 2014)

ameliorates intestinal cancer

modeled by Egfr^UAS.cBa

(Nászai et al., 2021)

Ras85D^JF02478

ameliorates colorectal cancer

modeled by SH3PX1^HMJ21552

(Zhang et al., 2019)

Ras85D^{G12V.UAS.Tag:FLAG,Tag:polyHis}

model of cancer

is exacerbated by Egfr^2.UAS

(Washington et al., 2020)

is ameliorated by Rabex-5^{DPYT.UAS.Tag:MYC}

(Washington et al., 2020)

is exacerbated by hop^JF01267

(Washington et al., 2020)

Ras85D^{Y4F.G12V.UAS.Tag:FLAG,Tag:polyHis}

model of cancer

is exacerbated by Egfr^2.UAS

(Washington et al., 2020)

is ameliorated by Rabex-5^{DPYT.UAS.Tag:MYC}

(Washington et al., 2020)

Ras85D^DN.UAS.cUa

ameliorates Alzheimer's disease 1

modeled by Hsap\APP^{Aβ42.UAS.cUa}

(Cheng et al., 2021)

p53

Models Based on Experimental Evidence ( 11 )

Allele

Disease

Evidence

References

p53^259H.GUS

model of cancer

CEA

(Sidorov and Belitskii, 2002)

p53^5A-1-4

model of testicular cancer

CEA

(Napoletano et al., 2017)

model of cancer

CEA

(de la Cova et al., 2014)

p53^E8

model of testicular cancer

CEA

(Napoletano et al., 2017)

p53^H159N.UAS.Ex

DOES NOT model cancer

CEA with pnut^GD1512

(Gerlach et al., 2018)

p53^GD4483

model of intestinal cancer

CEA with Apc^GD1333, Ras85D^V12.cUa.UAS

(Quintero and Bangi, 2023)

CEA with Apc^GD1333, Pten^RNAi.UAS.cUa, Ras85D^V12.cUa.UAS

(Quintero and Bangi, 2023)

CEA with Apc^GD1333, Med^GD1483, Ras85D^V12.cUa.UAS

(Quintero and Bangi, 2023)

model of cancer

CEA with Myc^UAS.cZa

(Diaz et al., 2024)

p53^GD11134

model of testicular cancer

CEA

(Napoletano et al., 2017)

p53^TM3

model of cancer

CEA with p53^-ns, Hsap\TP53^R175H

(D'Brot et al., 2017)

CEA with p53^-ns, Hsap\TP53^G245S

(D'Brot et al., 2017)

CEA with p53^-ns, Hsap\TP53^R248Q

(D'Brot et al., 2017)

CEA with p53^-ns, Hsap\TP53^R273C

(D'Brot et al., 2017)

CEA with p53^-ns, Hsap\TP53^R273H

(D'Brot et al., 2017)

p53^-ns

model of cancer

CEA with p53^TM3, Hsap\TP53^R175H

(D'Brot et al., 2017)

CEA with p53^TM3, Hsap\TP53^G245S

(D'Brot et al., 2017)

CEA with p53^TM3, Hsap\TP53^R248Q

(D'Brot et al., 2017)

CEA with p53^TM3, Hsap\TP53^R273C

(D'Brot et al., 2017)

CEA with p53^TM3, Hsap\TP53^R273H

(D'Brot et al., 2017)

p53^sgRNA.UAS

model of colorectal cancer

CEA with Ras85D^V12.cUa.UAS

(Zipper et al., 2022)

p53^{RNAi.UAS.RasG12D}

model of pancreatic ductal adenocarcinoma

CEA with CycE^{UAS.Tag:HA.Medsh}, Med^{RNAi.UAS.CycE-HA}, Ras85D^{G12D.UAS.p53sh}

(Sekiya et al., 2023)

CEA with CycE^{UAS.Tag:HA.Medsh}, Med^{RNAi.UAS.CycE-HA}, Ras85D^G12D.UAS.cSa

(Sekiya et al., 2023)

model of cancer

CEA with Myc^UAS.cZa

(Diaz et al., 2024)

p53^RNAi.UAS.cUa

model of colorectal cancer

CEA with Ras85D^V12.cUa.UAS, Pten^GD13500, Apc^RNAi.UAS.cUa, Med^RNAi.UAS.cUa

(Bangi et al., 2016)

CEA with Ras85D^V12.cUa.UAS, Pten^GD13500, Apc^RNAi.UAS.cUa

(Bangi et al., 2016)

CEA with Ras85D^V12.cUa.UAS, Apc^RNAi.UAS.cUa, Med^RNAi.UAS.cUa

(Bangi et al., 2016)

Modifiers Based on Experimental Evidence ( 15 )

Allele

Disease

Interaction

References

p53^11-1B-1

ameliorates Alexander disease

modeled by Hsap\GFAP^R79H.UAS

(Wang et al., 2015)

exacerbates tauopathy

modeled by Hsap\MAPT^R406W.UAS

(Merlo et al., 2014)

ameliorates brain ischemia

modeled by Mmus\Gria1^Lc.UAS

(Lei et al., 2017)

p53^259H.GUS

exacerbates Alzheimer's disease 1

modeled by Hsap\APP^{Arctic.Aβ42.UAS.Tag:SS(rPENK)}

(Iijima et al., 2010)

p53^5A-1-4

ameliorates Huntington's disease

modeled by Hsap\HTT^GMR.Q120

(Bae et al., 2005)

ameliorates cytochrome-c oxidase deficiency disease

modeled by Scox^GD898

(Martínez-Morentin et al., 2015)

exacerbates tauopathy

modeled by Hsap\MAPT^R406W.UAS

(Merlo et al., 2014)

p53^Ct.GUS

exacerbates Alzheimer's disease 1

modeled by Hsap\APP^{Arctic.Aβ42.UAS.Tag:SS(rPENK)}

(Iijima et al., 2010)

p53^GMR.Ex

ameliorates viral infectious disease

modeled by EBV\BRLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

exacerbates viral infectious disease

modeled by EBV\BZLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

ameliorates infectious mononucleosis

modeled by EBV\BRLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

exacerbates infectious mononucleosis

modeled by EBV\BZLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

ameliorates Epstein-Barr virus hepatitis

modeled by EBV\BRLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

exacerbates Epstein-Barr virus hepatitis

modeled by EBV\BZLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

p53^R155H.UAS.Ex

ameliorates ataxia telangiectasia

modeled by tefu^Δ356

(Song et al., 2004)

ameliorates cancer

modeled by Ptip³⁸⁰⁴, Ras85D^V12.cUa.UAS

(Dong et al., 2021)

p53^GL01032

ameliorates C9orf72 frontotemporal dementia and/or amyotrophic lateral sclerosis

modeled by Zzzz\GGGGCC^30.UAS.EGFP

(Maor-Nof et al., 2021)

p53^GD11134

model of testicular cancer

is NOT exacerbated by HtrA2^DF1

(Napoletano et al., 2017)

p53^KK113065

ameliorates cancer

modeled by Ptip³⁸⁰⁴, Ras85D^V12.cUa.UAS

(Dong et al., 2021)

p53^JF02513

ameliorates Alexander disease

modeled by Hsap\GFAP^R79H.UAS

(Wang et al., 2015)

p53^GL01220

ameliorates C9orf72 frontotemporal dementia and/or amyotrophic lateral sclerosis

modeled by Zzzz\GGGGCC^30.UAS.EGFP

(Maor-Nof et al., 2021)

exacerbates amyotrophic lateral sclerosis type 1

modeled by Hsap\SOD1^A4V.UAS

(Lu et al., 2019)

exacerbates C9orf72 frontotemporal dementia and/or amyotrophic lateral sclerosis

modeled by Zzzz\poly-PR^PO-100.UAS

(Lu et al., 2019)

p53^UAS.cUa

exacerbates cytochrome-c oxidase deficiency disease

modeled by Scox^GD898

(Martínez-Morentin et al., 2015)

exacerbates brain ischemia

modeled by Mmus\Gria1^Lc.UAS

(Lei et al., 2017)

exacerbates cancer

modeled by Ras85D^V12.cUa.UAS

(Dong et al., 2021)

p53^HMS02286

ameliorates C9orf72 frontotemporal dementia and/or amyotrophic lateral sclerosis

modeled by Zzzz\GGGGCC^30.UAS.EGFP

(Maor-Nof et al., 2021)

p53^DN.UAS.cUa

ameliorates cytochrome-c oxidase deficiency disease

modeled by Scox^GD898

(Martínez-Morentin et al., 2015)

ameliorates brain cancer

modeled by dpn^UAS.cUa

(Morrissy et al., 2016)

p53^RNAi.UAS.cUa

ameliorates Alzheimer's disease 1

modeled by Hsap\APP^{T12.Aβ42.UAS.Tag:SS(nec)}

(Taylor and Tuxworth, 2019)

CycE

Models Based on Experimental Evidence ( 3 )

Allele

Disease

Evidence

References

CycE^UAS.cRa

model of cancer

CEA

(Molano-Fernández et al., 2022)

model of prostate cancer

CEA

(Sekar et al., 2023)

CycE^{UAS.ORF.Tag:HA}

model of cancer

CEA

(Molano-Fernández et al., 2022)

CycE^{UAS.Tag:HA.Medsh}

model of pancreatic ductal adenocarcinoma

CEA with Med^{RNAi.UAS.CycE-HA}, Ras85D^{G12D.UAS.p53sh}, p53^{RNAi.UAS.RasG12D}

(Sekiya et al., 2023)

CEA with Med^{RNAi.UAS.CycE-HA}, Ras85D^G12D.UAS.cSa, p53^{RNAi.UAS.RasG12D}

(Sekiya et al., 2023)

Modifiers Based on Experimental Evidence ( 5 )

Allele

Disease

Interaction

References

CycE^HMS00060

ameliorates cancer

modeled by N^ICN.UAS

(Wang et al., 2021)

CycE⁰⁵²⁰⁶

exacerbates tuberous sclerosis

modeled by Tsc1^UAS.cTa, gig^UAS.cTa

(Tapon et al., 2001)

CycE^UAS.cLa

exacerbates tauopathy

modeled by Hsap\MAPT^{S202A.T205A.UAS}

(Steinhilb et al., 2007)

modeled by Hsap\MAPT^UAS.cWa

(Steinhilb et al., 2007)

modeled by Hsap\MAPT^{T231A.S235A.UAS}

(Steinhilb et al., 2007)

modeled by Hsap\MAPT^{S396A.S404A.UAS}

(Steinhilb et al., 2007)

ameliorates tuberous sclerosis

modeled by Tsc1^UAS.cTa, gig^UAS.cTa

(Tapon et al., 2001)

CycE^UAS.cUa

ameliorates neurodegenerative disease

modeled by Zzzz\CAG^{127Q.UAS.Tag:HA}

(Dubey and Tapadia, 2018)

CycE^k05007

exacerbates tauopathy

modeled by Hsap\MAPT^GMR.Ex.PJ

(Ambegaokar and Jackson, 2011)

Med

Models Based on Experimental Evidence ( 6 )

Allele

Disease

Evidence

References

Med^KK108412

model of juvenile polyposis syndrome

CEA

(Zhou and Boutros, 2020)

Med^GD1483

model of intestinal cancer

CEA with Apc^GD1333, Ras85D^V12.cUa.UAS, p53^GD4483

(Quintero and Bangi, 2023)

Med^RNAi.UAS.cUa

model of colorectal cancer

CEA with p53^RNAi.UAS.cUa, Pten^GD13500, Apc^RNAi.UAS.cUa, Ras85D^V12.cUa.UAS

(Bangi et al., 2016)

CEA with p53^RNAi.UAS.cUa, Apc^RNAi.UAS.cUa, Ras85D^V12.cUa.UAS

(Bangi et al., 2016)

CEA with Pten^GD13500, Apc^RNAi.UAS.cUa, Ras85D^V12.cUa.UAS

(Bangi et al., 2016)

Med^HD_CFD00386

model of intestinal cancer

CEA

(Zhou et al., 2021)

model of juvenile polyposis syndrome

CEA

(Zhou and Boutros, 2020)

Med^sgRNA.UAS

model of colorectal cancer

CEA with Ras85D^V12.cUa.UAS

(Zipper et al., 2022)

Med^{RNAi.UAS.CycE-HA}

model of pancreatic ductal adenocarcinoma

CEA with CycE^{UAS.Tag:HA.Medsh}, Ras85D^{G12D.UAS.p53sh}, p53^{RNAi.UAS.RasG12D}

(Sekiya et al., 2023)

CEA with CycE^{UAS.Tag:HA.Medsh}, Ras85D^G12D.UAS.cSa, p53^{RNAi.UAS.RasG12D}

(Sekiya et al., 2023)

Modifiers Based on Experimental Evidence ( 5 )

Allele

Disease

Interaction

References

Med¹³

ameliorates muscular dystrophy

modeled by Scgδ⁸⁴⁰

(Goldstein et al., 2011)

ameliorates cardiomyopathy

modeled by Scgδ⁸⁴⁰

(Goldstein et al., 2011)

Med¹⁵

ameliorates muscular dystrophy

modeled by Scgδ⁸⁴⁰

(Goldstein et al., 2011)

Med¹⁷

ameliorates muscular dystrophy

modeled by Scgδ⁸⁴⁰

(Goldstein et al., 2011)

Med^KK108412

model of juvenile polyposis syndrome

is ameliorated by bsk^DN.UAS

(Zhou and Boutros, 2020)

is exacerbated by puc^E69

(Zhou and Boutros, 2020)

Med^HD_CFD00386

model of intestinal cancer

is ameliorated by Rel^E20

(Zhou et al., 2021)

model of juvenile polyposis syndrome

is exacerbated by puc^E69

(Zhou and Boutros, 2020)

Alleles Representing Disease-Implicated Variants

Genetic Tools, Stocks and Reagents

Sources of Stocks

Contact lab of origin for a reagent not available from a public stock center.

Bloomington Stock Center Disease Page

Related mammalian, viral, bacterial, or synthetic transgenes

Allele

Transgene

Publicly Available Stocks

Hsap\SMAD4^UAS.cMa

P{UAS-MADH4.M}

Hsap\SMAD4^130S.UAS

P{UAS-Hsap\MADH4.S130}

Hsap\SMAD4^100T.UAS

P{UAS-Hsap\MADH4.100T}

Hsap\SMAD4^UASp.cSa

P{UASp-Smad4.S}

Hsap\SMAD4^K519R.UASp

P{UASp-Smad4.K519R}

Hsap\SMAD4^493H.UAS

P{UAS-Hsap\MADH4.493H}

Hsap\SMAD4^524ST.UAS

P{UAS-Hsap\MADH4.524ST}

Hsap\SMAD4^{Δ344-358.UAS}

P{UAS-Hsap\MADH4.Delta344-358}

Hsap\TP53^{UAS.C-Tag:MYC}

M{UAS-hp53.6xMyc}

Hsap\TP53^{ΔDBD.UAS.C-Tag:MYC}

M{UAS-hp53.DeltaDBD.6xMyc}

Hsap\TP53^{UAS.N-Tag:MYC}

M{UAS-6xMyc-hp53}

Hsap\TP53^{ΔDBD.UAS.N-Tag:MYC}

M{UAS-6xMyc-hp53.DeltaDBD}

Hsap\TP53^cH6FR.UAS

P{UAS-Hsap\TP53.cH6FR}

Hsap\TP53^cH5FR.UAS

P{UAS-Hsap\TP53.cH5FR}

P{UAS-Hsap\TP53.C234}

Hsap\TP53^UAS.cPa

P{UAS-Hsap\TP53.P}

Hsap\TP53^UASp.Tag:HA

Selected Drosophila transgenes

Allele

Transgene

Publicly Available Stocks

Ras85D^V152G.UASp

P{UASp-Ras85D.V152G}

Ras85D^{G12V.UAS.Tag:FLAG,Tag:polyHis}

P{UAS-FH-Ras85D.G12V}

Ras85D^{Y4F.G12V.UAS.Tag:FLAG,Tag:polyHis}

P{UAS-FH-Ras85D.Y4F.G12V}

Ras85D^V12.QUAS.cHa

P{QUAS-Ras85D.V12.H}

Ras85D^V12.QUAS.cLa

PBac{QUAS-Ras85D.V12.L}

Ras85D^{G12D.UAS.p53sh}

P{UAS-Ras85D(G12D).UAS-p53(shRNA)}

Ras85D^V12.UAS

P{UAS-Ras85D.V12}

w¹¹¹⁸; P{UAS-Ras85D.V12}TL1

Ras85D^N17.UAS

P{UAS-Ras85D.N17}

P{UAS-Ras85D.N17}TL1, w¹¹¹⁸

P{UAS-Ras85D.V12.S35}

P{UAS-Apc,Apc2,p53,Med,Pten,cic.sgRNA}

p53^Ct.GUS

P{GUS-p53.Ct}

w¹¹¹⁸; P{GUS-p53.Ct}3.1/TM6B, Tb¹

p53^259H.GUS

P{GUS-p53.259H}

w¹¹¹⁸; P{GUS-p53.259H}3.1

p53^R155H.UAS.Ex

P{UAS-p53.R155H.Ex}

y¹ w¹¹¹⁸; P{UAS-p53.R155H.Ex}2/T(2;3)TSTL, CyO: TM6B, Tb⁺

p53^H159N.UAS.Ex

P{UAS-p53.H159N.Ex}

y¹ w¹¹¹⁸; P{UAS-p53.H159N.Ex}2

p53^GMR.Ex

P{GMR-p53.Ex}

P{GMR-p53.Ex}1, y¹ w¹¹¹⁸/FM7c

CycE^{UAS.Tag:HA.Medsh}

PBac{UAS-CycE(HA).UAS-Med(shRNA)}

y¹ w^*; P{UAS-CycE.L}ML1

CycE^UAS.cUa

P{UAS-CycE.U}

CycE^{UAS.ORF.Tag:HA}

M{UAS-CycE.ORF.3xHA}

M{UAS-CycE.ORF.3xHA}ZH-86Fb

Med^HD_CFD00386

P{HD_CFD00386}

P{hsFLP}1, y¹ w¹¹¹⁸; P{HD_CFD00386}attP40/CyO-GFP

Med^sgRNA.UAS

P{UAS-Apc,Apc2,p53,Med,Pten,cic.sgRNA}

RNAi constructs available

Allele

Transgene

Publicly Available Stocks

Ras85D^{TH201501177.S}

w¹¹¹⁸; P{GD12553}v28129

y¹ v¹; P{TRiP.JF02478}attP2

y¹ sc^* v¹ sev²¹; P{TRiP.HMS01294}attP2

Ras85D^GL00336

P{TRiP.GL00336}

y¹ sc^* v¹ sev²¹; P{TRiP.GL00336}attP2/TM3, Sb¹

p53^RNAi.sg

PBac{sg-p53.RNAi}

p53^{RNAi.UAS.RasG12D}

P{UAS-Ras85D(G12D).UAS-p53(shRNA)}

w¹¹¹⁸; P{GD4483}v10692

p53^GD11134

P{GD11134}

w¹¹¹⁸; P{GD11134}v45139

y¹ v¹; P{TRiP.JF02513}attP2

p53^GL01032

P{TRiP.GL01032}

y¹ sc^* v¹ sev²¹; P{TRiP.GL01032}attP2

y¹ v¹; P{TRiP.GL01220}attP40

p53^HMS02286

P{TRiP.HMS02286}

y¹ sc^* v¹ sev²¹; P{TRiP.HMS02286}attP2

CycE^GD14749

P{GD14749}

w¹¹¹⁸; P{GD14749}v47941

CycE^JF02473

P{TRiP.JF02473}

y¹ v¹; P{TRiP.JF02473}attP2

CycE^HMS00060

P{TRiP.HMS00060}

y¹ sc^* v¹ sev²¹; P{TRiP.HMS00060}attP2

y¹ sc^* v¹ sev²¹; P{TRiP.GL00511}attP40

y¹ sc^* v¹ sev²¹; P{TRiP.GL00673}attP2

Med^{RNAi.UAS.CycE-HA}

PBac{UAS-CycE(HA).UAS-Med(shRNA)}

y¹ v¹; P{TRiP.JF02218}attP2

Med^GD1483

P{GD1483}

w¹¹¹⁸; P{GD1483}v19688

Med^GL01313

P{TRiP.GL01313}

y¹ sc^* v¹ sev²¹; P{TRiP.GL01313}attP40

Selected Drosophila classical alleles

Allele

Allele class

Mutagen

Publicly Available Stocks

Ras85D⁰⁶⁶⁷⁷

P-element activity

P{PZ}Ras85D⁰⁶⁶⁷⁷ ry⁵⁰⁶/TM3, ry^RK Sb¹ Ser¹

Ras85D^e2F

sev¹⁴; Ras85D^e2F/TM3, Sb¹

Ras85D^e1B

ethyl methanesulfonate

sev¹⁴; Ras85D^e1B/TM3, Sb¹

Ras85D^unspecified

Ras85D^ΔC40B

loss of function allele

Ras85D^x7b

loss of function allele

P-element activity

Ras85D^Δ17b

amorphic allele - genetic evidence

p53^TM3

amorphic allele - genetic evidence

p53^5A-1-4

ends-in gene targeting

y¹ w¹¹¹⁸; p53^5A-1-4

p53^E8

amorphic allele - molecular evidence

Delta2-3 transposase

p53^E4

amorphic allele - molecular evidence

Delta2-3 transposase

p53^11-1B-1

ends-in gene targeting

y¹ w¹¹¹⁸; p53^11-1B-1

p53^-ns

ends-in gene targeting

w¹¹¹⁸/Dp(1;Y)y⁺; TI{TI}p53^-ns

CycE⁰⁵²⁰⁶

P-element activity

P{PZ}CycE⁰⁵²⁰⁶ cn¹/CyO; ry⁵⁰⁶

CycE^k05007

P-element activity

y¹ w^67c23; P{lacW}CycE^k05007/CyO

CycE^KG00239

loss of function allele

P-element activity

y^d2 w¹¹¹⁸ P{ey-FLP.N}2 P{5xglBS-lacZ.38-1}TPN1; P{SUPor-P}CycE^KG00239 P{neoFRT}40A/CyO y⁺

CycE^AR95

loss of function allele

ethyl methanesulfonate

w^*; CycE^AR95 cn¹ pr¹ bw¹ wx^wxt/CyO, P{ftz-lacB}E3

Med¹³

ethyl methanesulfonate

ru¹ hry¹ P{neoFRT}82B sr¹ e^s Med¹³/TM3, Sb¹

Med¹⁵

ethyl methanesulfonate

Med¹⁷

ethyl methanesulfonate

Med⁸

loss of function allele

Med³

loss of function allele

ethyl methanesulfonate

Med^C246

loss of function allele

References (7)

Report Sections

Open Close